Learn About Undifferentiated Pleomorphic Sarcoma

What is the definition of Undifferentiated Pleomorphic Sarcoma?
Undifferentiated pleomorphic sarcoma (UPS), also known as malignant fibrous histiocytoma, is a rare, aggressive soft tissue or bone cancer that usually occurs in the arms or legs in the sixth or seventh decade of life.
Save information for later
Sign Up
What are the symptoms of Undifferentiated Pleomorphic Sarcoma?
Symptoms of undifferentiated pleomorphic sarcoma may include the presence of a mostly painless, rapidly enlarging nodule in the lower extremities (especially the thigh), upper arms, head and neck, retroperitoneum, viscera, distal or proximal femur (upper leg), proximal tibia (lower leg), or humerus (upper arm). Additional symptoms of undifferentiated pleomorphic sarcoma may include pain, swelling, malaise, lack of appetite, constipation, fever, and weight loss.
Not sure about your diagnosis?
Check Your Symptoms
What are the current treatments for Undifferentiated Pleomorphic Sarcoma?
Treatment for undifferentiated pleomorphic sarcoma depends on the location but may include surgery, radiation therapy, chemotherapy (ifosfamide, trabectedin, dacarbazine, and pazopanib), targeted therapy, and immunotherapy.
Who are the top Undifferentiated Pleomorphic Sarcoma Local Doctors?
Learn about our expert tiers
Learn more
What are the latest Undifferentiated Pleomorphic Sarcoma Clinical Trials?
A Phase 2, Open-label, Single Arm, Multicohort, Multicenter Trial to Evaluate the Efficacy and Safety of JCAR017 in Adult Subjects With Relapsed or Refractory Indolent B-cell Non-Hodgkin Lymphoma (NHL)

Summary: This is a global Phase 2, open-label, single-arm, multicohort, multicenter study to evaluate efficacy and safety of JCAR017 in adult subjects with r/r FL or MZL. The study will be conducted in compliance with the International Council on Harmonisation (ICH) of Technical Requirements for Registration of Pharmaceuticals for Human Use/Good Clinical Practice (GCP) and applicable regulatory requirement...

Match to trials
Find the right clinical trials for you in under a minute
Get started
Phase 1/2 Dose Escalation Study of CD19/CD22 Bicistronic Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory CD19/CD22-expressing B Cell Malignancies

Background: Acute lymphoblastic leukemia (ALL) is the most common cancer in children. About 90% of children and young adults who are treated for ALL can now be cured. But if the disease comes back, the survival rate drops to less than 50%. Better treatments are needed for ALL relapses.

What are the Latest Advances for Undifferentiated Pleomorphic Sarcoma?
Busulfan/thiotepa followed by autologous peripheral blood stem cell transplantation for refractory diffuse large B-cell lymphoma accompanied by hypopyon.
Underwater endoscopic mucosal resection of upper gastrointestinal subepithelial tumors: A case series pilot study (with video).
Tired of the same old research?
Check Latest Advances
A randomised phase II trial of a trivalent ganglioside vaccine targeting GM2, GD2 and GD3 combined with immunological adjuvant OPT-821 versus OPT-821 alone in metastatic sarcoma patients rendered disease-free by surgery.